Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aripiprazole and escitalopram combination versus monotherapy in major depressive disorder with incomplete response to escitalopram
2010-018796-21Phase 3Terminated
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Jul 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of aripiprazole and escitalopram in major depressive disorder (MDD) (11 arms), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoint: Mean change in MADRS Total Score from Week 8 to Week 14. Started Jul 2010; status: terminated.
02
Drugs
aripiprazoleescitalopram
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2010-018796-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018796-21.